Outpatient Prospective Payment System (OPPS): Redetermination Requests for Drugs Acquired under 340B Program

Published 04/23/2021

340B Acquired Drugs
The 340B drug pricing program is a federal program that allows certain federally designated healthcare entities to purchase drugs at a discounted rate. As of January 1, 2018, Medicare has reimbursed hospitals who bill under OPPS at a rate of the average sales price (ASP), 22.5 percent, for drugs purchased through the 340B Drug Program.

Appeals
In accordance with Medicare’s national payment policy for drugs acquired under the 340B drug program, drugs reimbursed under OPPS are not eligible for an administrative review. Appeal requests received by Palmetto GBA will be dismissed.


Was this article helpful?

Palmetto GBA Web Chat

Sounds: OnSave Transcript
Please answer the questions below. Additional fields may appear based on previous answers. Fields with a red asterisk (*) are required.
Your InformationClear
1()-x
Inquiry InformationClear
Select your stateClear
Select your stateClear
Provider InformationClear
Patient InformationClear
Patient Name must exactly match the information submitted on the claim, including suffix if applicable.
//
Appeal InformationClear
//
//
Claim InformationClear
//
//
Denial InformationClear
//
//
Rejection InformationClear
DDE InformationClear
Restore InformationClear
//
Prior Authorization InformationClear
//
//
Application InformationClear
Product InformationClear
OtherClear
Additional InformationClear

Are you sure you want to end your chat?

Keep ChattingClose ChatSave Transcript & Close

Webchat

Our dedicated webchat representatives are online to assist you with your general inquiries, provider enrollment, EDI, eServices and more in real-time.